Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines.
1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and nine other antiherpesviral nucleoside analogues were compared for their potencies against four strains of varicella-zoster virus (VZV) on three different cell lines: HEL cells, Vero cells, and MS cells established from a human malignant schwannoma. In contrast to the activity against herpes simplex virus type 1 previously reported, BV-araU showed extremely marked antiviral activity against VZV even on Vero cells. ED50, 50% plaque reduction dose, of BV-araU for VZV was 0.20-3.1 and 0.14-0.63 ng/ml on Vero cells and on HEL cells, respectively. Potency of BV-araU on MS cells was similar to that on these cell lines. There was not significant variation in anti-VZV activities of other nucleoside analogues on these three different cell lines except a few combinations of VZV strain and test compound.
Machida
H
H
Biology Laboratory, Yamasa Shoyu Co., Ltd., Chiba.
Ijichi
K
K
Ohta
A
A
Honda
M
M
Niimura
M
M
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D014645:Herpesvirus 3, Human / Q000187:drug effects*; D006801:Humans; D014407:Tumor Cells, Cultured; D014709:Vero Cells / Q000382:microbiology
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C031368:sorivudine